Vancomycin

This classification denotes an antibiotic with the molecular formula C66H75Cl2N9O24, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q205EH1VU, chemically known as (s(sub a))-(3s,6r,7r,22r,23s,26s,36r,38ar)-44-((2-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-lyxo-hexopyranosyl)-beta-d-glucopyranosyl)oxy)-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-((2r)-4-methyl-2-(methylamino)valeramido)-2,5,24,38,39-pentaoxo-22h-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35- but generally known as vancomycin, which bears US NIH Compound Identifier 14969. European Medicines Agency schedules Vancomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05076MIG. The term VANCOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules vancomycin in its Anatomical Therapeutic Chemical (ATC) Classification. VANCOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule vancomycin under HS 29419000 and SITC 54139. As of Q4 2014, VANCOMYCIN remains the US FDA Preferred Term for this commodity. Vancomycin bears US NLM identifiers UMLS ID C0042313 and NCI Concept Code C925. SMILES: CLC1C2OC3C(OC4OC(C(O)C(O)C4OC4OC(C(O)C(N)(C4)C)C)CO)C4OC5C(CL)CC(C(O)C6NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC)CC(C)C)C(O)C(C1)CC2)CC(=O)N)C(C3)C4)C1CC(C2C(C(NC6=O)C(=O)O)CC(O)CC2O)C(O)CC1)CC5.